Hepatitis C research and re-transmission of good Gilead dominance is unbreakable
September 23, 2015 Source: Bio Valley
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];As we all know, Gilead quickly climbed the peak of the hepatitis C treatment market with its Sovaldi and cocktail therapy Harvoni, so many old biomedical giants had to go down the drain. Not only that, but for the foreseeable future, Gilead seems to be firmly occupying the top spot in the field. Recently, another phase III clinical trial of the company's combination therapy for hepatitis C cocktail therapy has further conveyed the good strength of Gilead in this field.
Although Gilead is invincible in the hepatitis C treatment market, the company has not stopped developing new treatments for a moment. The company has previously conducted a study on the combination of Sovaldi and another NS5A inhibitor, the new drug velpatasvir, and promoted four clinical phase III studies. According to the latest research data, this combination therapy has achieved good results in hepatitis C patients with multiple genotypes.
The first three clinical phase III trials tested the extent of response to this new therapy in patients with genotype 1 - genotype 6 hepatitis C. The data showed that after 12 weeks of combined treatment, the rate of sustained cure (SVR12) in patients with hepatitis C treated with new therapy reached 98%. The patient group in the fourth clinical study was mainly patients with type B cirrhosis in children. The study found that SVR12 reached 83% and 86% at 12 weeks and 24 weeks, respectively, compared with ribavirin. This figure then rose to 94%.
According to Gilead's plan, Harvoni will be mainly used in patients with genotype 1 hepatitis C, and the new Sov/Vel combination therapy will cover the population of patients with type 2-6 hepatitis C. Gilead will use this to weave a large network covering the entire genotype of hepatitis C patients, further increasing the threshold for the hepatitis C drug market.
The hepatitis C drug market is far from coming to an end. Abbott has launched its own hepatitis C cocktail therapy, and Merck is also steadily advancing its research on hepatitis C drug therapy. However, no matter how many companies will advance into this field in the future, Gilead will be a mountain in front of them.
Potato,Dehydrated Potatoes,Dried Potato Cubes,Dehydrated potato Round Flakes,Air Dried Potato
Jiangsu Tiankang Food Co., Ltd. , https://www.tiankangfood.com